GlassScriptPhysician profile
Robin F Roth
NPI 1841249067
$2,111.96
in general payments reported to CMS, 2019-2025
19 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $128 · 2021: $81.74 · 2022: $118 · 2023: $197 · 2024: $501 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,116.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $368.54 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $361.49 | 2019-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $280.87 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $241.87 | 2019-2024 | Farxiga, Breztri |
| Cvrx, INC. | $131.39 | 2024 | Barostim Neo System |
| Lilly USA, LLC | $125.00 | 2019-2025 | Kisunla, Jardiance, Zepbound |
| Allergan, INC. | $90.63 | 2019-2020 | |
| Glaxosmithkline, LLC. | $90.28 | 2019-2023 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $80.72 | 2019-2021 | |
| Novo Nordisk INC | $76.81 | 2019-2024 | Rybelsus, Ozempic |
| Currax Pharmaceuticals LLC | $46.30 | 2021-2024 | Contrave |
| Merck Sharp & Dohme LLC | $44.09 | 2019-2025 | Capvaxive, Gardasil 9 |
| Boston Scientific Corporation | $35.37 | 2025 | Axonics |
| Eisai INC. | $33.14 | 2025 | |
| Pfizer INC. | $25.23 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $24.94 | 2025 | Nexletol |
| Amarin Pharma, INC. | $24.80 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.13 | 2019 | |
| Siemens Medical Solutions USA, INC. | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.